Urinary Tract Infection
The Diagnostic Dilemma
For years physicians have used a urine culture to detect urinary tract infections. UTIs are some of the most common bacterial infections, affecting 150 million people each year worldwide. Traditional urinary cultures take a long time to get results typically 5-7 days and are not sensitive or accurate in detecting disease. In fact, urinary cultures will miss up to 2/3 of the patients that have UTI and 50% of the patients with severe urinary symptoms underlining the need for more effective methods of diagnosis. Delayed turnaround time of results and inaccuracy of the diagnostic tool cost the healthcare system over 10 billion dollars a year and create unnecessary patient anxiety and stress.
A2Z Diagnostics developed and launched a UTI molecular solution that provides a timely and accurate answer. Our panel utilizes molecular techniques such as polymerase chain reaction (PCR) to identify the bacteria causing the infection. This type of test is more sensitive than traditional methods of diagnosing a UTI and can detect bacterial strains that would otherwise be missed. By extracting DNA from the patient's urine sample, our PCR testing uses advanced biotechnology to identify specific targeted pathogens that most commonly are associated with urinary tract infections. In addition to our bacteria and fungal targets, we also offer antibiotic resistance marker detection which gives us the ability to test for the presence of any markers in the pathogens of interest. These antibiotic resistance markers in conjunction with our UTI panel will further assist physicians to make proper and more effective clinical evaluations and conclusions.
Molecular UTI testing can provide quick and accurate results and can be used to tailor treatment for the specific strain of bacteria causing the infection. Results are often available within hours allowing for more rapid initiation of directed treatment.
OB/GYN • Primary Care Providers • Urologists • Long term care facilities • Pain management physicians or doctors • Infectious disease clinicians
Targeted Treatments, Accurate Outcomes.
Based on DNA Evidence
EMR INTEGRATIONS • ACCEPTS MOST INSURANCE
ACCURATE RESULTS • QUICK TURN AROUND TIME
- Acinetobacter baumannii
- Aerococcus urinae
- Candida albicans
- Candida parapsilosis
- Citrobacter freundii
- Corynebacterium riegelii
- Enterobacter aerogenes
- Escherichia coli
- Streptococcus anginosus
- Mycoplasma genitalium
- Pseudomonas aeruginosa
- Staphylococcus aureus
- Streptococcus agalactiae
- Actinobaculum schaalii
- Alloscardovia omnicolens
- Candida glabrata
- Klebsiella pneumoniae
- Citrobacter koseri
- Corynebacterium urealyticum
- Enterococcus faecalis
- Klebsiella oxytoca
- Morganella morganii
- Proteus mirabilis
- Serratia marcescens
- Staphylococcus saprophyticus
- Ampicillin / Sulbactam
- Trimethoprim / Sulfamethoxazole
- Piperacilin / Tazabactam
- Alloscardovia omnicolens
Within 24hrs we provide a semi quantitative report with bacteria load
Physicians Portal Available for Access to Results
- Nausea and vomiting
- Strong and frequent urge to urinate
- Cloudy, bloody, or strong-smelling urine
- Pain / burning sensation when urinating
- Muscle aches and abdominal pains
- Catheters users may only experience fever
MEDICATIONS THAT MAY INCREASE THE RISK
- Alferon N
- Asacol tablets / rectal susp.
- Balsalazide tablets
- Benazepril Hydrochloride
- Canasa tablets
- Colazal tablets / rectal susp.
- Dipentum tablets / rectal susp.
- Inerferon Alfa
- Intron A
- Loniten tablets
- Medroxyprogesterone Acetate
- Mesalamine tablets
- Micardis / Micardis HCT
- Minoxidil tablets
- Olsalazine tablets
- Pentasa tablets / rectal susp.
- Rowasa tablets / rectal susp.
AT RISK PATIENTS
- Controlled Substance patients
- Heart Disease
- Patients on long term care regimens
- Chronic pain care patients
COMMONLY USED SUBSTANCES LIKE OPIODS, KETAMINE, NSAID’S, ANETHETICS AND NEURAXIAL ANETHETICS ALL TEND TO RESULT IN INCREASED RISK OF UTI INFECTIONS.